ARCHIVES

Dear FDA: Provenge Provokes Letters From Opponents, Advocates, Investors.

This article is from The Cancer Letter archive.

Vol. 33 No. 16 | April 27, 2007

Download PDF Visit The Full Archive

Related Articles

NCI To Fund Partnerships Between Cancer Centers and Minority Institutions

November 12, 1999

Economic Analyses Of New Therapies Useful In Phase III Studies, Trialists Say

July 24, 2009

FDA Approves Gleevec For First Line Rx Of CML

January 31, 2003

Ellence Has Lower Risk Of Heart Damage, Study Finds

August 27, 2004

In Brief: PHS Established Two Scientific Integrity Offices; Workshop On Ethical Issues Planned

August 18, 1989

Proceedings Initiated Against Two Physicians At Dana-Farber

April 7, 1995